Asset
IMETELSTAT SODIUM
Geron Corporation Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05371964 | phase1 | active_not_recruiting | 2022-05-04 | 2027-02-01 | Geron Corporation | A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis |
| NCT01256762 | phase2 | completed | 2010-11-01 | 2012-10-01 | Geron Corporation | Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer |
| NCT00310895 | phase1 | completed | 2006-03-01 | 2013-03-01 | Geron Corporation | Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies |
| NCT00594126 | phase1 | completed | 2007-11-01 | 2011-07-01 | Geron Corporation | Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma |
| NCT00718601 | phase1 | completed | 2008-07-01 | 2011-10-01 | Geron Corporation | Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 217779 | NDA | GERON CORP |
Marketed products (2)
- RYTELO
- RYTELO